PrimerAntitüberküloz İlaçlara Dirençli MycobacterumTuberculosis Kompleks İzolatlarında Dirençle İlişkili Yaygın Mutasyonların Araştırılması

• Published in: Dicle tıp dergisi Vol. 51; no. 3; pp. 461 - 469
• Main Authors: Şahin, İbrahim Halil, Akpolat, Nezahat, Yakıcı, Gülfer, Özcan, Nida
• Format: Journal Article
• Language: Turkish
• Published: Diyarbakir Dicle University 01.09.2024
• Subjects: Automation; Drug resistance; Genotype & phenotype; Life sciences; Mutation; Tuberculosis
• ISSN: 1300-2945; 1308-9889
• DOI: 10.5798/dicletip.l552636

Methods: MTBC isolates obtained from clinical samples at the mycobacteriology laboratory of Dicle University Hospital from January 2014 to August 2019 were included. Results: TCG/TTG mutation at codon 531 of rpoB gene was the common mutation responsible for resistance in 19 (57.6%) RIF resistant isolates, AGC/ACC mutation in katG315 gene region in 14 (46.7%) INH resistant isolates and C/T mutations at position -15 of inhA gene region in 8 (26.7%) INH resistant isolates. Conclusion: The genotypic test (GenoType MTBDR plus) used to identify mutations associated with resistance to primary antituberculosis drugs revealed that the most common mutations linked to rifampicin resistance were the TCG/TTG mutation located at codon 531 of the rpoB gene, the AGC/ACC (Ser315Thr) mutation located at codon 315 of the katG gene, and C/T mutations at position -15 in the inhA gene region. The AGC/ACC (Ser315Thr) mutation at codon 315 of the katG gene and C/T mutations at position -15 of the inhA gene region were identified as the most common contributors to resistance, aligning with results from earlier studies on the subject.